Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
Status:
Suspended
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Clinical study of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid
tumors. The primary objective is to determine the maximum tolerated dose and dose limiting
toxicity of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid tumors